Summary:
In patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) risk, Curcumin supplementation significantly improved clinical outcomes including glycemic control, lipid profile, and reduced ASCVD risk compared to placebo treatment,
though it was associated with mild gastrointestinal discomfort in some patients.
| PICO | Description |
|---|---|
| Population | Patients with type 2 diabetes mellitus (T2DM) and an atherosclerotic cardiovascular disease (ASCVD) risk score of ≥ 5%. |
| Intervention | Curcumin supplementation alongside standard diabetes management therapy. |
| Comparison | Placebo treatment alongside standard diabetes management therapy. |
| Outcome | Curcumin supplementation significantly reduced HbA1c levels, improved lipid profiles (e.g., lowered LDL and triglycerides), and decreased ASCVD risk scores. Mild gastrointestinal discomfort was reported as the main side effect in a subset of patients. |
Source: Omar M El-Rakabawy, et al. “Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk.” Read article here.
